Xenetic Biosciences, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $660.6K | $806.9K | $766.3K | $1.0M | $589.9K | $593.3K | $648.8K | $614.2K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $552.0K | $661.4K | $773.4K | $756.5K | $656.6K | $879.0K | $1.0M | $368.0K |
| SG&A Expense | $1.1M | $647.6K | $615.9K | $815.2K | $657.8K | $656.6K | $705.7K | $745.7K |
| Operating Income | $-971.7K | $-502.1K | $-623.0K | $-544.7K | $-724.4K | $-942.4K | $-1.1M | $-499.5K |
| Operating Margin | -147.1% | -62.2% | -81.3% | -53.0% | -122.8% | -158.9% | -169.4% | -81.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-929.7K | $-456.4K | $-579.1K | $-509.9K | $-688.7K | $-903.1K | $-1.1M | $-436.7K |
| Net Margin | -140.7% | -56.6% | -75.6% | -49.7% | -116.7% | -152.2% | -162.5% | -71.1% |
| EPS (Basic) | $-0.41 | $-0.20 | $-0.21 | $-0.33 | $-0.45 | $-0.59 | $-0.68 | $-0.28 |
| EPS (Diluted) | $-0.41 | $-0.20 | $-0.21 | $-0.33 | $-0.45 | $-0.59 | $-0.68 | $-0.28 |
| Shares Outstanding (Basic) | 2.3M | 2.3M | 1.7M | 1.5M | 1.5M | 1.5M | 1.5M | 1.5M |
| Shares Outstanding (Diluted) | 2.3M | 2.3M | 1.7M | 1.5M | 1.5M | 1.5M | 1.5M | 1.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |